OspA

https://clinicaltrials.gov/ct2/show/NCT03970733

Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis

Study Type : Interventional (Clinical Trial)
Actual Enrollment : 246 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Alternative Schedule Study For VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged 18 To 65 Years – A Randomized, Controlled, Observer-Blind Phase 2 Study
Actual Study Start Date : June 26, 2019
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : March 2021

https://clinicaltrials.gov/ct2/show/NCT03769194

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study

Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis

Study Type : Interventional (Clinical Trial)
Actual Enrollment : 573 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. A Randomized, Controlled, Observer-blind Phase 2 Study.
Actual Study Start Date : December 17, 2018
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : October 2020
Resource links provided by the National Library of Medicine

https://clinicaltrials.gov/ct2/show/NCT03010228

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

Study Type : Interventional (Clinical Trial)
Actual Enrollment : 179 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years
Actual Study Start Date : January 2017
Actual Primary Completion Date : September 28, 2017
Actual Study Completion Date : January 16, 2019